Form 4: Genprex Director Brent Longnecker Sells Shares

Director Brent Longnecker sold a total of 18 shares of Genprex, Inc. common stock for tax purposes.

Summary

• Director Brent Longnecker executed a sale of 18 shares of Genprex, Inc. (GNPX) common stock on April 14, 2026.
• The shares were sold at a price of $1.23 per share.
• 8 shares were sold directly by the reporting person.
• 10 shares were sold indirectly through Longnecker Associates Ltd.
• The transaction was conducted to satisfy tax obligations.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale is a de minimis transaction specifically identified for tax purposes.

Positives

• The transaction was explicitly disclosed as being for tax purposes, which is a routine financial management activity rather than a signal of lack of confidence in the company.

Negatives

• Insider selling, regardless of the reason, can sometimes be perceived negatively by retail investors.

Risks

• The company remains subject to market volatility and the inherent risks associated with its sector.

Future Outlook

No forward-looking guidance or strategic outlook was provided in this filing.

Industry Context

StockSavvy.ai notes that routine insider sales for tax purposes are common in the biotechnology and pharmaceutical sectors and generally do not reflect a change in corporate strategy or outlook.

Comparison to Industry Standards

• The volume of shares sold is negligible and consistent with standard tax-related divestment practices observed among corporate directors in the small-cap biotech industry.

Stakeholder Impact

• Minimal impact on shareholders given the insignificant volume of shares sold.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

Genprex, GNPX, Insider Trading, Form 4, SEC Filing, Brent Longnecker